US · MBX · BIOTECHNOLOGY
MBX Biosciences, Inc. Common Stock (MBX) intrinsic value and stock valuation
$49.55as of 2026-11-21 · Mkt cap 3.21B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
MBX Biosciences, Inc. Common Stock DCF and intrinsic value
InvestorsCraft values MBX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MBX’s statements →
MBX Biosciences, Inc. Common Stock Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2022–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-98.06M | -$-68.19M | -$-35.31M | -$-25.16M |
| Net income | -$-86.97M | -$-61.92M | -$-32.56M | -$-26.14M |
| EPSd | -$-2.38M | -$-1.85M | -$-1.02M | -$-820.72K |
| Operating cash flow | -$-79.95M | -$-54.68M | -$-31.98M | -$-23.12M |
| Capital expenditure | -$-1.93M | -$-870K | -$-130K | -$-440K |
| Free cash flow | -$-81.88M | -$-55.55M | -$-32.11M | -$-23.56M |
| Total assets | $385.1M | $268.5M | $84.2M | $45.1M |
| Total debt | $600K | $170K | $320K | $460K |
| Net debt | -$-74.69M | -$-49.18M | -$-30.2M | -$-23.75M |
| Total equity | $369.2M | $257.4M | -$-72.47M | -$-42.6M |
| Cash and short-term investments | $373.7M | $262.2M | $80.7M | $42.5M |
Income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $250K | $0.00 | $0.00 | $0.00 |
| Gross profit | -$-250K | $0.00 | $0.00 | $0.00 |
| Research and development expenses | $79.2M | $57.4M | $28.5M | $21.4M |
| Selling, general and administrative expenses | $18.9M | $10.8M | $6.78M | $3.76M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $98.1M | $68.2M | $35.3M | $25.2M |
| Cost and expenses | $98.1M | $68.2M | $35.3M | $25.2M |
| Interest income | $11.1M | $6.27M | $2.75M | $370K |
| Interest expense | $0.00 | $0.00 | $0.00 | $370K |
| Depreciation and amortization | $250K | $240K | $160K | $60K |
| Ebitda | -$-86.72M | -$-61.68M | -$-32.41M | -$-25.7M |
| Operating income | -$-98.06M | -$-68.19M | -$-35.31M | -$-25.16M |
| Total other income/expenses, net | $11.1M | $6.27M | $2.75M | -$-970K |
| Income before tax | -$-86.97M | -$-61.92M | -$-32.56M | -$-26.14M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-86.97M | -$-61.92M | -$-32.56M | -$-26.14M |
| Weighted average shares outstanding | $36.5M | $33.4M | $31.9M | $31.9M |
| Weighted average diluted shares outstanding | $36.5M | $33.4M | $31.9M | $31.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Cash and short-term investments | $373.7M | $262.2M | $80.7M | $42.5M |
| Net receivables | $2.12M | $680K | $210K | $140K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $381.5M | $267.3M | $83.5M | $44.2M |
| Property, plant and equipment, net | $3.22M | $1.2M | $670K | $840K |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $3.6M | $1.25M | $710K | $880K |
| Total assets | $385.1M | $268.5M | $84.2M | $45.1M |
| Accounts payable | $2.98M | $5.33M | $1.39M | $980K |
| Short-term debt | $170K | $170K | $150K | $140K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $15.5M | $11.1M | $3.93M | $3.43M |
| Long-term debt | $420K | $0.00 | $170K | $320K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $430K | $40K | $152.7M | $84.3M |
| Capital lease obligations | $170K | $170K | $320K | $460K |
| Total liabilities | $15.9M | $11.1M | $156.7M | $87.7M |
| Common stock | $10K | $10K | $0.00 | $0.00 |
| Retained earnings | -$-224.48M | -$-137.5M | -$-75.58M | -$-43.02M |
| Accumulated other comprehensive income (loss) | $290K | $60K | $60K | $0.00 |
| Total equity | $369.2M | $257.4M | -$-72.47M | -$-42.6M |
| Total investments | $298.4M | $212.8M | $50.2M | $18.3M |
| Total debt | $600K | $170K | $320K | $460K |
| Net debt | -$-74.69M | -$-49.18M | -$-30.2M | -$-23.75M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Net income | -$-86.97M | -$-61.92M | -$-32.56M | -$-26.14M |
| Depreciation and amortization | -$-3.61M | $240K | $160K | $60K |
| Stock-based compensation | $8.68M | $5.22M | $2.04M | $310K |
| Change in working capital | $1.57M | $4.6M | -$-730K | $1.29M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-2.46M | $3.93M | $410K | $670K |
| Net cash provided by operating activities | -$-79.95M | -$-54.68M | -$-31.98M | -$-23.12M |
| Investments in property, plant and equipment | -$-1.93M | -$-870K | -$-130K | -$-440K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-83.7M | -$-160.59M | -$-30.93M | -$-11.41M |
| Common stock issued | $189.6M | $174.5M | $740K | $30K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $189.6M | $234.1M | $69.2M | $46.1M |
| Net change in cash | $25.9M | $18.8M | $6.31M | $11.5M |
| Cash at end of period | $75.3M | $49.4M | $30.5M | $24.2M |
| Operating cash flow | -$-79.95M | -$-54.68M | -$-31.98M | -$-23.12M |
| Capital expenditure | -$-1.93M | -$-870K | -$-130K | -$-440K |
| Free cash flow | -$-81.88M | -$-55.55M | -$-32.11M | -$-23.56M |
Line items
Line items
Line items
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
- CEO
- Steve Hoerter
- Employees
- 63
- Beta
- 0.10
Explore
Frequently asked questions
What is the intrinsic value of MBX Biosciences, Inc. Common Stock (MBX)?
InvestorsCraft does not currently publish an intrinsic value for MBX. How the IC value is calculated.
Is MBX undervalued?
InvestorsCraft does not publish an undervaluation signal for MBX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.